Waldencast's Obagi Medical Gains FDA Nod for New Hyaluronic Acid Filler
Event summary
- FDA approved Obagi® saypha® ChIQ™ injectable hyaluronic acid gel on June 15, 2026.
- Product developed by Croma-Pharma, utilizing MACRO Core Technology for stable 3D HA matrix.
- Indicated for cheek augmentation and midface contour correction in patients over 21.
- Expands Obagi Medical's portfolio following the launch of Obagi® saypha® MagIQ™ in January 2026.
- ALOHA Program data shows 94% of injectors believe Obagi® saypha® MagIQ™ complements existing filler options.
The big picture
Waldencast continues to execute on its strategy of building a comprehensive beauty and wellness platform by expanding Obagi Medical's product portfolio. The FDA approval of Obagi® saypha® ChIQ™ strengthens Obagi's position in the fast-growing U.S. dermal filler category, leveraging the brand's legacy in advanced skincare and medical aesthetics. The company's focus on integrated solutions aims to capture a larger share of the aesthetic market, where professional skincare and injectable treatments are increasingly converging.
What we're watching
- Market Penetration
- How Obagi® saypha® ChIQ™ will perform in the competitive U.S. dermal filler market.
- Integration Strategy
- Whether Waldencast can sustain the momentum of its Obagi Medical acquisitions.
- Cross-Selling Potential
- The pace at which Obagi can increase attachment rates of skincare products with injectable treatments.